Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Rangering i aksjer #7142
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Aksjekurs
$40.39
Sist synkronisert: 2023-08-18
Markedsverdi
$1.70B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Chinook Therapeutics, Inc. (KDNY)

Kategori

Antall utestående aksjer for Chinook Therapeutics, Inc. (KDNY)
Antall utestående aksjer per August 2026: 0
Ifølge Chinook Therapeutics, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 0. Ved slutten av August 2026 hadde selskapet 0 utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Chinook Therapeutics, Inc. (KDNY) fra 2026 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
Ikke nok data for de angitte datoene.
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
253.90M -
US
62.19M -
NL
478.91M -
AU
396.00M -
US
- -
CH